

Media Release

Hyphens Pharma and medac Extend Metoject® Agreement to Thailand and Cambodia

- **Territory extension of the Metoject® subcutaneous autoinjector pen into Thailand and Cambodia**
- **Builds upon the existing agreement covering Singapore, Malaysia, the Philippines, and Vietnam**

Singapore, 16 OCT 2025 – Hyphens Pharma Pte. Ltd., a subsidiary of Hyphens Pharma International Limited, Singapore’s leading specialty pharmaceutical and consumer healthcare group (“**Hyphens Pharma**”, “凯帆药剂国际有限公司”, or the “**Company**”, and its subsidiaries, the “**Group**”), is pleased to announce the extension of its partnership with Medac Gesellschaft für klinische Spezialpräparate m.b.H. (“**medac**”) to include Thailand and Cambodia for the commercialisation of the Metoject® subcutaneous autoinjector pen.

This territory extension builds upon the existing agreement signed in March 2025, which granted Hyphens Pharma exclusive rights to register and commercialise the Metoject® subcutaneous autoinjector pen in Singapore, Malaysia, the Philippines, and Vietnam. With the inclusion of Thailand and Cambodia, Hyphens Pharma further strengthens its footprint in Southeast Asia, reinforcing its commitment to bringing innovative treatments across the region.



Metoject® subcutaneous autoinjector pen

The Metoject® subcutaneous autoinjector pen is currently approved and available in over 15 countries in Europe, the United States and Japan, and well-recognised as a first-line treatment for rheumatoid arthritis under both the European and American guidelines.¹ The subcutaneous methotrexate injection treatment is indicated for patients with rheumatoid arthritis and plaque psoriasis, offering a therapeutic option with better bioavailability and reduced gastrointestinal side effects compared to oral methotrexate.²

Mr Frank Lucaßen, CEO of medac, commented, *“With Hyphens we have found a great partner in Southeast Asia for the commercialisation of our innovative pharmaceutical products. We are excited to further develop our partnership and to keep working together on granting access to our treatment to even more patients in the region.”*

¹ Smolen JS, et al. Ann Rheum Dis. 2023 Jan;82(1):3-18 & Arnold MJ. Am Fam Physician. 2022;106(3):340-342

² Rutkowska-Sak L, et al. Reumatologia 2009; 47 (4) 207-211 & Cipriani P, et al. Clin Ther 2014; 36(3) 427-435

Mr Lim See Wah (林世华), Executive Chairman and CEO of Hyphens Pharma, added: *“We’re happy to deepen our partnership with medac and bring the Metoject® autoinjector pen to more patients in Southeast Asia. This expansion into Thailand and Cambodia not only reflects our shared vision of making high-quality, effective treatments available to those in need, but also enriches our product portfolio in these countries, further cementing Hyphens Pharma’s position as ASEAN’s specialty pharma company.”*

This development is not expected to have a material impact on Hyphens Pharma’s net tangible assets or earnings per share for the current financial year.

End.

About Hyphens Pharma International Limited (<http://www.hyphensgroup.com>)

Hyphens Pharma International Limited and its subsidiaries (the "Group") is Singapore’s leading specialty pharmaceutical and consumer healthcare group, leveraging its diverse footprint in ASEAN countries. The Group has a direct presence in Singapore, Vietnam, Malaysia, Indonesia and the Philippines, and is supplemented by a marketing and distribution network covering 15 other markets – Bangladesh, Brunei, Cambodia, Hong Kong S.A.R., Macau S.A.R., Myanmar, South Korea, Sri Lanka, Thailand and Gulf Cooperation Council countries, including Bahrain, Kuwait, Oman, Qatar, Saudi Arabia and United Arab Emirates.

The Group is headquartered in Singapore, where its strategic planning, finance, regulatory affairs, research and development, legal, business development and logistics operations are based. The Group’s core business comprises the following segments: Pharmaceutical and Medical Aesthetics, Proprietary Brands, and Digital Platform and E-Pharmacy. Besides marketing and selling a range of specialty pharmaceutical products in selected ASEAN countries through exclusive distributorship or licensing and supply agreements with brand principals mainly from Europe and the United States, the Group also develops, markets and sells its own proprietary range of dermatological products and health supplement products. Additionally, the Group operates a medical hypermart catering to healthcare providers and retail pharmacies, as well as an e-pharmacy pharmacy for doctors to prescribe medications for home delivery to their patients.

About Medac Gesellschaft für klinische Spezialpräparate m.b.H. (www.medac-group.com)

Medac Gesellschaft für klinische Spezialpräparate m.b.H. and its subsidiaries (the “medac group”) produces and distributes medical products in four key areas: rheumatology, urology, haematology and oncology. At medac group, we believe that health is humanity’s most valuable resource. Since 1970, our mission has been to improve patients’ quality of life worldwide by making the best medical treatments available. As a globally operating pharmaceutical company headquartered in Germany, we provide high quality medical treatments for patients worldwide in more than 90 countries. With more than 2,000 employees we are committed to improving human health.

Our products are manufactured in Germany and other European countries to the highest standards, utilizing our own logistics center and production sites, and subsequently distributed worldwide. We are constantly working to improve authorized medicines and to develop innovative therapies in the fields of rheumatology, urology, haematology, and oncology. Part of our mission is to provide safe, high-quality and innovative original products, as well as generics and biosimilars. In this way, we make vital treatments accessible to those affected.

Issued on behalf of	: Hyphens Pharma International Limited
For media enquires contact	: Ms Chong Yi Sze / Ms Karina Choo / Mr Gerald Woon
Email / DID / Mobile	: yisze.chong@hyphens.com.sg / (65) 9729 6694 karina@cogentcomms.com / (65) 6704 9280 / (65) 9107 6991 woon@cogentcomms.com / (65) 6704 9268 / (65) 9694 8364

This media release has been reviewed by the Company's sponsor, SAC Capital Private Limited (the "Sponsor"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "SGX-ST") and the SGX-ST assumes no responsibility for the contents of this media release, including the correctness of any of the statements or opinions made or reports contained in this media release.

The contact person for the Sponsor is Ms Lee Khai Yinn (Tel: (65) 6232 3210) at 1 Robinson Road, #21-01 AIA Tower, Singapore 048542.